

Djuna L Cahen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/839028/publications.pdf>

Version: 2024-02-01

28
papers

1,202
citations

623734

14
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

1605
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	12.1	357
2	Long-term Outcomes of Endoscopic vs Surgical Drainage of the Pancreatic Duct in Patients With Chronic Pancreatitis. <i>Gastroenterology</i> , 2011, 141, 1690-1695.	1.3	263
3	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. <i>Diabetologia</i> , 2016, 59, 2588-2593.	6.3	105
4	Long-term yield of pancreatic cancer surveillance in high-risk individuals. <i>Gut</i> , 2022, 71, 1152-1160.	12.1	84
5	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. <i>Gastroenterology</i> , 2022, 162, 772-785.e4.	1.3	60
6	Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1217-1225.	4.4	39
7	GLP-1 based therapies: clinical implications for gastroenterologists. <i>Gut</i> , 2016, 65, 702-711.	12.1	34
8	A biodegradable non-covered self-expandable stent to treat pancreatic duct strictures in chronic pancreatitis: a proof of principle. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 486-491.	1.0	32
9	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. <i>BMJ Open</i> , 2015, 5, e009579.	1.9	30
10	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2021, 47, 101223.	2.9	25
11	Predictors of Progression Among Low-Risk Intraductal Papillary Mucinous Neoplasms in a Multicenter Surveillance Cohort. <i>Pancreas</i> , 2018, 47, 471-476.	1.1	22
12	Surveillance for neoplasia in the pancreas. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 971-986.	2.4	21
13	Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 789-799.	3.7	21
14	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. <i>Diabetes Care</i> , 2017, 40, 301-308.	8.6	15
15	Optimization of Pancreatic Juice Collection: A First Step Toward Biomarker Discovery and Early Detection of Pancreatic Cancer. <i>American Journal of Gastroenterology</i> , 2020, 115, 2103-2108.	0.4	14
16	Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic <i>CDKN2A</i> variants. <i>Journal of Medical Genetics</i> , 2021, 58, 264-269.	3.2	13
17	Testing for Anti-PBP Antibody Is Not Useful in Diagnosing Autoimmune Pancreatitis. <i>American Journal of Gastroenterology</i> , 2016, 111, 1650-1654.	0.4	11
18	Follow-up of asymptomatic pancreatic cysts in clinical practice: A vignette questionnaire. <i>Pancreatology</i> , 2016, 16, 416-422.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. <i>Endoscopy International Open</i> , 2018, 06, E541-E548.	1.8	8
20	Pancreatic cyst surveillance imposes low psychological burden. <i>Pancreatology</i> , 2019, 19, 1061-1066.	1.1	8
21	Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. <i>International Journal of Cancer</i> , 2021, 149, 337-346.	5.1	8
22	Protein biomarkers in pancreatic juice and serum for identification of pancreatic cancer. <i>Gastrointestinal Endoscopy</i> , 2022, 96, 801-813.e2.	1.0	8
23	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. <i>Familial Cancer</i> , 2020, 19, 247-258.	1.9	7
24	International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression. <i>United European Gastroenterology Journal</i> , 2022, 10, 169-178.	3.8	6
25	Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00465.	2.5	3
26	Editorial: when, who and how—the ever-evolving management of pancreatic cystic lesions. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 829-830.	3.7	0
27	Fully covered self-expandable metal stents for benign biliary strictures: an effective alternative. <i>Endoscopy</i> , 2020, 52, 334-335.	1.8	0
28	Endoscopic radiofrequency ablation to prolong survival for unresectable extrahepatic biliary cancer. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 101-102.	1.0	0